Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$3.17 USD
-0.02 (-0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.17 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Income Statements
Fiscal Year end for Acumen Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 1 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 1 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 61 | 45 | 20 | 9 | 10 |
Income After Depreciation & Amortization | -61 | -45 | -20 | -8 | -8 |
Non-Operating Income | 9 | 2 | -81 | 1 | 0 |
Interest Expense | 1 | 0 | 0 | 0 | 0 |
Pretax Income | -52 | -43 | -101 | -7 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -43 | -101 | -7 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -43 | -101 | -7 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -64 | -45 | -19 | -8 | -8 |
Depreciation & Amortization (Cash Flow) | -3 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -61 | -45 | -20 | -8 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 48.61 | 40.60 | 20.06 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.08 | -1.06 | -2.13 | NA | NA |
Diluted Net EPS (GAAP) | -1.08 | -1.06 | -5.02 | -17.48 | NA |
Fiscal Year end for Acumen Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 18.48 | 16.04 | 13.48 | 13.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.48 | -16.04 | -13.48 | -13.13 |
Non-Operating Income | NA | 2.56 | 3.08 | 1.87 | 1.84 |
Interest Expense | NA | 0.58 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -16.51 | -12.96 | -11.61 | -11.30 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -16.51 | -12.96 | -11.61 | -11.30 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -16.50 | -12.96 | -11.61 | -11.31 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 57.18 | 54.23 | 41.03 | 41.03 |
Diluted EPS Before Non-Recurring Items | NA | -0.29 | -0.24 | -0.28 | -0.28 |
Diluted Net EPS (GAAP) | NA | -0.28 | -0.24 | -0.28 | -0.28 |